BioPharmSignal logoBioPharmSignal

Biotech News

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

Fate Therapeutics (FATE)Fate TherapeuticsCompany update

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique ability to traffic to tumor site and functionally persist without the reliance on

Open original release

Related news

FATEFate Therapeutics2026-05-11 12:30 EST

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

RLAYRelay Therapeutics2026-05-19 10:00 EST

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

View all latest news

Fate Therapeutics

Fate Therapeutics is a cell-therapy company focused on engineered immune cells and off-the-shelf approaches to cancer and immune disease. Its strategy has long centered on platform ambition in cell therapy.

Recent company news

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

FATEFate Therapeutics2026-06-04 12:30 EST

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Stock data

Close
2.43 USD
Market cap
299.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States